MediWound (STU:M8W) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:M8W MediWound Ltd STU:M8W
70 GF Score
Price €11.40
GF Value €10.46
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is MediWound Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:M8W
70GF Score
MediWound Ltd STU:M8W
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MediWound (STU:M8W) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of €11.40 is trading 9% above its estimated GF Value™ of €10.46. GuruFocus considers MediWound to be Fairly Valued.

Key valuation signals for STU:M8W:

  • Short Ratio:
  • GF Value™: €10.46 vs. price of €11.40 (9% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the STU:M8W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediWound Business Description

Other Exchanges MDWD:USAM8W:Germany
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd. is an Israeli biopharmaceutical company that develops, manufactures, and commercializes biologic therapeutics for severe burns, chronic and hard-to-heal wounds, and related indications. Its lead product, NexoBrid, is an FDA- and EMA-approved orphan biologic for enzymatic eschar removal in severe burns, offering an alternative to surgical debridement. The company also develops EscharEx, a bromelain-based candidate for debridement of chronic wounds such as venous leg ulcers and diabetic foot ulcers, and MW005 for non-melanoma skin cancer. MediWound sells primarily to hospitals, burn centers, and wound care specialists, with the United States as its largest market and additional revenue from Europe and other international markets. Its revenue model combines direct product sales with licensing, distribution, and partnership arrangements, including government stockpiling contracts for burn mass casualty preparedness.
70GF Score

Get the complete analysis for STU:M8W

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.40
Price
€10.46
GF Value